{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:10:20Z","timestamp":1790179820686,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Naval Medical University Campus fund","award":["2023QN100"],"award-info":[{"award-number":["2023QN100"]}]},{"name":"Naval medical center fund","award":["23M2501"],"award-info":[{"award-number":["23M2501"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82300235"],"award-info":[{"award-number":["82300235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Health Commission Talent Plan Youth Project","award":["2022YQ031"],"award-info":[{"award-number":["2022YQ031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00277-024-06163-3","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:20:05Z","timestamp":1736029205000},"page":"1023-1037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Metabolic reprogramming induced by PSMA4 overexpression facilitates bortezomib resistance in multiple myeloma"],"prefix":"10.1007","volume":"104","author":[{"given":"Han","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"issue":"10272","key":"6163_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397(10272):410\u2013427","journal-title":"Lancet"},{"issue":"1","key":"6163_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1):149\u2013157","journal-title":"Leukemia"},{"issue":"13","key":"6163_CR3","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","volume":"113","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F et al (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113(13):3040\u20133049","journal-title":"Blood"},{"issue":"4","key":"6163_CR4","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M et al (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67(4):1783\u20131792","journal-title":"Cancer Res"},{"issue":"8","key":"6163_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1517\/13543784.2012.691164","volume":"21","author":"EM Ocio","year":"2012","unstructured":"Ocio EM, Mateos MV, San-Miguel JF (2012) Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs. Expert Opin Investig Drugs 21(8):1075\u20131087","journal-title":"Expert Opin Investig Drugs"},{"key":"6163_CR6","doi-asserted-by":"publisher","unstructured":"Gavriatopoulou M, Paschou SA, Ntanasis-Stathopoulos I, Dimopoulos MA (2021) Metabolic disorders in multiple myeloma. Int J Mol Sci 22(21):11430. https:\/\/doi.org\/10.3390\/ijms222111430","DOI":"10.3390\/ijms222111430"},{"issue":"6","key":"6163_CR7","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1021\/acs.jproteome.1c00022","volume":"20","author":"DC Koomen","year":"2021","unstructured":"Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B et al (2021) Metabolic changes are associated with melphalan resistance in multiple myeloma. J Proteome Res 20(6):3134\u20133149","journal-title":"J Proteome Res"},{"issue":"10","key":"6163_CR8","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-14-3400","volume":"75","author":"P Maiso","year":"2015","unstructured":"Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y et al (2015) Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res 75(10):2071\u20132082","journal-title":"Cancer Res"},{"key":"6163_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00284","volume":"8","author":"B Wegiel","year":"2018","unstructured":"Wegiel B, Vuerich M, Daneshmandi S, Seth P (2018) Metabolic switch in the tumor microenvironment determines immune responses to anti-cancer therapy. Front Oncol 8:284","journal-title":"Front Oncol"},{"key":"6163_CR10","doi-asserted-by":"publisher","unstructured":"Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E (2021) The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. Int J Mol Sci 22(9):4462. https:\/\/doi.org\/10.3390\/ijms22094462","DOI":"10.3390\/ijms22094462"},{"issue":"1","key":"6163_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"SK Rehman","year":"2021","unstructured":"Rehman SK, Haynes J, Collignon E, Brown KR, Wang Y, Nixon AML et al (2021) Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell 184(1):226\u2013242 (e21)","journal-title":"Cell"},{"issue":"4","key":"6163_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","volume":"26","author":"KM Lee","year":"2017","unstructured":"Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE et al (2017) MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab 26(4):633\u2013647 (e7)","journal-title":"Cell Metab"},{"issue":"7","key":"6163_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.tim.2021.12.011","volume":"30","author":"J Foo","year":"2022","unstructured":"Foo J, Bellot G, Pervaiz S, Alonso S (2022) Mitochondria-mediated oxidative stress during viral infection. Trends Microbiol 30(7):679\u2013692","journal-title":"Trends Microbiol"},{"issue":"1","key":"6163_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","volume":"120","author":"M Cavo","year":"2012","unstructured":"Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D et al (2012) Bortezomib-Thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120(1):9\u201319","journal-title":"Blood"},{"key":"6163_CR15","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV et al (2017) Multiple myeloma. Nat Rev Dis Primers 3:17046","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"6163_CR16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S (2014) Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 18(6):947\u2013961","journal-title":"J Cell Mol Med"},{"issue":"6","key":"6163_CR17","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR et al (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112(6):2489\u20132499","journal-title":"Blood"},{"issue":"5","key":"6163_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2016.03.026","volume":"29","author":"XD Zhang","year":"2016","unstructured":"Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW et al (2016) Tight junction protein 1 modulates proteasome capacity and proteasome inhibitor sensitivity in multiple myeloma via EGFR\/JAK1\/STAT3 signaling. Cancer Cell 29(5):639\u2013652","journal-title":"Cancer Cell"},{"issue":"1","key":"6163_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12964-024-01628-4","volume":"22","author":"T Li","year":"2024","unstructured":"Li T, Xiao P, Qiu D, Yang A, Chen Q, Lin J et al (2024) NCX1\/Ca(2+) promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFkappaB signaling pathway. Cell Commun Signal 22(1):258","journal-title":"Cell Commun Signal"},{"issue":"7","key":"6163_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/bloodadvances.2022008442","volume":"7","author":"I Spaan","year":"2023","unstructured":"Spaan I, van Nieuwenhuijzen N, Kimman T, Rockx-Brouwer D, Tieland RG, Maurice MM et al (2023) Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma. Blood Adv 7(7):1103\u20131107","journal-title":"Blood Adv"},{"issue":"1","key":"6163_CR21","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1038\/s41467-022-34654-2","volume":"13","author":"A Vdovin","year":"2022","unstructured":"Vdovin A, Jelinek T, Zihala D, Sevcikova T, Durech M, Sahinbegovic H et al (2022) The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. Nat Commun 13(1):6820","journal-title":"Nat Commun"},{"issue":"2","key":"6163_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","volume":"33","author":"S Barrio","year":"2019","unstructured":"Barrio S, Stuhmer T, Da-Via M, Barrio-Garcia C, Lehners N, Besse A et al (2019) Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 33(2):447\u2013456","journal-title":"Leukemia"},{"issue":"10","key":"6163_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Martinez-Reyes","year":"2021","unstructured":"Martinez-Reyes I, Chandel NS (2021) Cancer metabolism: looking forward. Nat Rev Cancer 21(10):669\u2013680","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"6163_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-020-00320-2","volume":"21","author":"G Bergers","year":"2021","unstructured":"Bergers G, Fendt SM (2021) The metabolism of cancer cells during metastasis. Nat Rev Cancer 21(3):162\u2013180","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6163_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1039\/D1MO00106J","volume":"18","author":"EA Zaal","year":"2022","unstructured":"Zaal EA, de Grooth HJ, Oudaert I, Langerhorst P, Levantovsky S, van Slobbe GJJ et al (2022) Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma. Mol Omics 18(1):19\u201330","journal-title":"Mol Omics"},{"key":"6163_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40170-017-0169-9","volume":"5","author":"EA Zaal","year":"2017","unstructured":"Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR (2017) Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab 5:7","journal-title":"Cancer Metab"},{"issue":"11","key":"6163_CR27","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/leu.2016.102","volume":"30","author":"GP Soriano","year":"2016","unstructured":"Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N et al (2016) Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia 30(11):2198\u20132207","journal-title":"Leukemia"},{"issue":"28","key":"6163_CR28","doi-asserted-by":"publisher","first-page":"46691","DOI":"10.18632\/oncotarget.17358","volume":"8","author":"C Chen","year":"2017","unstructured":"Chen C, Lou T (2017) Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget 8(28):46691\u201346703","journal-title":"Oncotarget"},{"key":"6163_CR29","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.2147\/DDDT.S274980","volume":"14","author":"RL Li","year":"2020","unstructured":"Li RL, He LY, Zhang Q, Liu J, Lu F, Duan HX et al (2020) HIF-1alpha is a potential molecular target for herbal medicine to treat diseases. Drug Des Devel Ther 14:4915\u20134949","journal-title":"Drug Des Devel Ther"},{"key":"6163_CR30","doi-asserted-by":"publisher","first-page":"1064661","DOI":"10.3389\/fphar.2022.1064661","volume":"13","author":"S Luo","year":"2022","unstructured":"Luo S, Jiang Y, Anfu Z, Zhao Y, Wu X, Li M et al (2022) Targeting hypoxia-inducible factors for breast cancer therapy: a narrative review. Front Pharmacol 13:1064661","journal-title":"Front Pharmacol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06163-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06163-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06163-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T16:35:44Z","timestamp":1743870944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06163-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6163"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06163-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read, edited, and approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}